JP Morgan Chase
KYTX icon

JP Morgan Chase’s Kyverna Therapeutics KYTX Stock Holding History

JP Morgan Chase’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.4K Buy
4,675
+401
+9% +$3.34K ﹤0.01% 6337
2025
Q4 		$40.2K Sell
4,274
-2,401
-36% -$17.8K ﹤0.01% 6312
2025
Q3 		$40K Sell
6,675
-21,180
-76% -$84.7K ﹤0.01% 6304
2025
Q2 		$85.5K Sell
27,855
-11,647
-29% -$28.8K ﹤0.01% 5677
2025
Q1 		$76.2K Sell
39,502
-2,126,935
-98% -$6.28M ﹤0.01% 5697
2024
Q4 		$8.1M Sell
2,166,437
-220,915
-9% -$1.06M ﹤0.01% 2898
2024
Q3 		$11.7M Buy
2,387,352
+326,095
+16% +$2.51M ﹤0.01% 2478
2024
Q2 		$15.5M Buy
2,061,257
+1,216,792
+144% +$18.6M ﹤0.01% 2074
2024
Q1 		$21M Buy
+844,465
New +$23.6M ﹤0.01% 1849

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

JP Morgan Chase's KYTX Position: Q1 2026 in Review

JP Morgan Chase increased its Kyverna Therapeutics (KYTX) stake by 9.4% in Q1 2026, buying an estimated $3.34K and bringing the position to 4,675 shares worth $35.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6337.

JP Morgan Chase first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $21M in Q1 2024. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • JP Morgan Chase held 4,675 shares of Kyverna Therapeutics worth $35.4K as of Q1 2026.
  • JP Morgan Chase bought 401 Kyverna Therapeutics shares in Q1 2026, an estimated $3.34K.
  • Kyverna Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6337 holding.
  • JP Morgan Chase first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • JP Morgan Chase's Kyverna Therapeutics position peaked at $21M in Q1 2024.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.